Navamedic ASA: Mandatory notification of trade

Publisert: 02.09.2026

Navamedic ASA: Growth and double-digit adjusted EBITDA margin in Q2 and first half 2026

Publisert: 14.08.2026

Navamedic ASA: Invitation to presentation of second quarter and first half year 2026 results

Publisert: 10.08.2026

Navamedic ASA: Mandatory notification of trade

Publisert: 26.06.2026

Navamedic ASA: Change in leadership

Publisert: 16.06.2026

Navamedic launches Virono®– the first single-dose over-the-counter cold sore tablet

Publisert: 21.05.2026